The EphA2 and cancer connection: potential for immune-based interventions

Area of Science:

• Molecular Biology
• Cell Signaling
• Oncology

Background:

• Eph receptors, the largest receptor tyrosine kinase subfamily, mediate cell-cell interactions.
• Eph receptors are vital for tissue organization, homeostasis, and adult processes like angiogenesis and stem cell differentiation.
• Eph receptors can act as tumor promoters or suppressors, with EphA2 dysregulation linked to cancer pathology.

Purpose of the Study:

• To highlight the role of EphA2 in specific cancers, including glioblastoma, prostate, ovarian, uterine, gastric, melanoma, and breast cancer.
• To review current therapeutic strategies targeting EphA2.
• To discuss novel peptide-based agonists for EphA2 receptor.

Main Methods:

• Review of literature on EphA2 expression and function in various cancer types.
• Analysis of pre-clinical and clinical data for monoclonal antibody (mAb) therapies targeting EphA2.
• Examination of recent studies on peptide and cyclic-peptide agonists for EphA2.

Main Results:

• EphA2 is frequently overexpressed or mutated in various cancers, correlating with poor prognosis.
• Monoclonal antibodies targeting EphA2 are a key therapeutic strategy, with several in pre-clinical and clinical development.
• Novel peptides and cyclic-peptides show promise as selective EphA2 receptor agonists.

Conclusions:

• EphA2 is a significant therapeutic target in multiple cancer types.
• mAb-based therapies and peptide agonists represent promising avenues for EphA2-targeted cancer treatment.
• Further research into EphA2-targeted therapies could improve patient outcomes in various malignancies.